Alendronate and atrial fibrillation: A meta-analysis of randomized placebo-controlled clinical trials

Osteoporosis International

Volumn 23, Issue 1, 2012, Pages 233-245

  Barrett Connor, E ^a   Swern, A S ^b   Hustad, C M ^c   Bone, H G ^d   Liberman, U A ^e   Papapoulos, S ^f   Wang, H ^c   De Papp, A ^c   Santora, A C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CELGENE CORPORATION   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Michigan Bone and Mineral Clinic   (United States)

^e TEL AVIV UNIVERSITY   (Israel)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alendronate; Atrial fibrillation; Bisphosphonate; Clinical trial; Placebo

Indexed keywords

ALENDRONIC ACID; PLACEBO;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ALENDRONATE; ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INCIDENCE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857356298     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1546-9     Document Type: Article

References (30)

1. Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370-2375 (Pubitemid 32424106)
2. Miyasaka Y, Barnes ME, Gersh BJ et al (2006) Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114:119-125 (Pubitemid 44420743)
3. Lloyd-Jones DM, Wang TJ, Leip EP et al (2004) Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110:1042-1046 (Pubitemid 39319000)
4. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822 (Pubitemid 46698462)
5. Cummings SR, Schwarz AV, Black DM (2007) Alendronate and atrial fibrillation. N Engl J Med 356:1895-1896
6. Karam R, Camm J, McClung M (2007) Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 357:712-713 (Pubitemid 47267247)
7. Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809 (Pubitemid 350044800)
8. Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS (2009) Bisphosphonate and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord 10:113
9. Camm AJ (2010) Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin Therap 32:426-436
10. Lewiecki EM, Cooper C, Thompson E et al (2010) Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract 64:821-826
11. Loke YK, Jeevanantham V, Singh S (2009) Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 32:219-228
12. Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in metaanalysis of sparse data. Stat Med 23:1351-1375 (Pubitemid 38594143)
13. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR (2007) Much ado about nothing: a comparison of the performance of metaanalytical methods with rare events. Stat Med 26:53-77 (Pubitemid 46099417)
14. Sutton AJ, Cooper NJ, Lambert PC et al (2002) Meta-analysis of rate and adverse event data. Exp Rev Pharmacoeconomics Outcomes Res 2:367-379
15. US Food and Drug Administration (2008) Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates. Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm. Accessed 5 November 2009
16. Heckbert SR, Li G, Cummings SR et al (2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826-831 (Pubitemid 351649266)
17. Abrahamsen B, Eiken P, Brixen K (2009) Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 265:581-592
18. Bhuriya R, Singh M, Molnar J et al (2010) Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 142:213-217
19. Huang WF, Tsai Y-W, Wen Y-W et al (2010) Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause 17:57-63
20. Bunch TJ, Anderson JL, May HT et al (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824-828
21. Grosso A, Douglas I, Hingorani A et al (2009) Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a selfcontrolled case-series safety analysis. PLoS ONE 4:e4720
22. Sørensen HT, Christensen S, Mehnert F et al (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336:813-816 (Pubitemid 351548223)
23. Vestergaard P, Schwartz K, Pinholt EM et al (2010) Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcif Tissue Int 86:335-342
24. Recker RR, Lewiecki EM, Miller PD, Reiffel J (2009) Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 122 (2 Suppl):S22-S32
25. von der Recke P, Hansen MA, Hassager C (1999) The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106:271-278
26. Pazianas M, Compston J, Huang CL-H (2010) Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 25:2-10
27. Kemeny-Suss N, Kasneci A, Rivas D et al (2010) Alendronate affects calcium dynamics in cardiomyocytes in vitro. Vascul Pharmacol 51:350-358
28. Morrison TB, Bunch TJ, Gersh BJ (2009) Pathophysiology of concomitant atrial fibrillation and heart failure: implications for management. Nat Clin Pract Cardiovasc Med 6:46-56
29. Olkin I, Sampson A (1998) Comparison of meta-analysis versus analysis of variance of individual patient data. Biometrics 54:317-322 (Pubitemid 28158806)
30. Mathew T, Nordstrom K (1999) On the equivalence of metaanalysis using literature and using individual patient data. Biometrics 55:1221-1223